OncRef

Clinical Trial: NCT02227251

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:Karyopharm Therapeutics Inc
Information Provided By:Karyopharm Therapeutics Inc
Last Update Posted:2026-10-01

Study Overview

Brief Summary

A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.

Official Title

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Conditions

Diffuse Large B-cell Lymphoma

Intervention / Treatment

  • Drug: Selinexor
  • Drug: Selinexor
  • Drug: Selinexor

Other Study ID Numbers

  • KCP-330-009
  • 2014-001977-15
  • 2014

Start Date (Actual)

2014-11

Primary Completion Date (Estimated)

2026-12

Study Completion Date (Estimated)

2026-12

Enrollment (Estimated)

244

Study Type

Interventional

Phase

Phase 2